FDA 483 - CSL Behring (Australia) Pty Ltd
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of CSL Behring Australia Proprietary Ltd, a manufacturer of plasma derivatives, revealed significant deficiencies in their manufacturing process controls. The firm failed to establish adequate procedures for monitoring the output of manufacturing processes, specifically regarding the assessment and monitoring of internal in-process control specifications for their U.S. licensed IVIG product. Additionally, the company did not submit required Biological Product Deviation Reports for numerous complaints of cracked or broken vials.
- Product Type
- Biologics
ID · 7b2f4dac-7728-4213-addb-6a988a425a1c